Mesenchymal Stem Cells – Advances & Applications Size and Share Published in 2015-07-01 Available for US$ 4295 at Researchmoz.us
This global strategic report is produced for:
Management of stem cell companies
Management of regenerative therapy companies
Stem cell industry investors
It is designed to increase your efficiency and effectiveness in:
Commercializing mesenchymal stem cell (MSC) products, technologies, and therapies
Making intelligent investment decisions
Launching high-demand products
Selling effectively to your client base
Increasing revenue from MSC products and services
Taking market share from your competition
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.
MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologous mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more.
This global strategic report explores recent advances in MSC research applications, research priorities by market segment, and the competitive environment for MSC research products. It also identifies trend and growth patterns within the MSC industry. Because it is important for pharmaceutical companies interested to understand underlying forces affecting the MSC market, this report also presents a range of topics that apply to these companies, including how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.
Literature and data concerning the biology and differentiation potential of mesenchymal stem cells (MSCs) has expanded rapidly over the past 10 years, with more than 13,000 publications now exploring aspects of MSC biology, behavior, and applications. In particular, MSCs appear to be an exceptionally promising tool for cell therapy because of their unusual characteristics, which partially mimic those of embryonic stem cells, while having advantages in terms of availability, expandability, transplantability, and ethical implications.
Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as from their ability to migrate to sites of tissue injury/inflammation or tumor growth. These localization properties present a promising strategy for targeted introduction of therapeutic agents through MSC gene therapy. In addition, MSCs possess strong immunosuppressive properties that medical researchers are exploiting for both autologous as well as heterologous therapies.
Clinical Progress with MSCs
As mentioned, mesenchymal stem cells (MSCs) have inspired a lot of activity over the past ten years as a novel therapeutic model for a wide range of diseases. Presently, MSCs-based clinical trials are being conducted for twelve types of disease conditions, with many completed trials showing their safety and efficacy.
The clinical utility of MSCs are mostly attributed to their four key biological properties, which are their potential to:
Migrate to sites of inflammation caused by tissue injury when injected intravenously
To get differentiated into different cell types
To release different bioactive molecules having the potential of stimulating recovery of injured cells and preventing inflammation
To accomplish immunomodulatory functions
Get a Sample Copy of the Report: http://www.researchmoz.us/enquiry.php?type=S&repid=301052
Currently, there are 128 clinical trials involving MSCs are in progress in different parts of the world, including China, the European Union, the United States, the Middle East, and South Korea. Among these trials, 45 (35%) are exploiting MSCs for various disease indications. Currently, four major clinical trials using MSCs have reached Phase III. Stempeutics Research’s product candidate Stempeucel is being evaluated in two centers for treating critical leg ischemia. Prochymal is the product candidate from Osiris Therapeutics and it is being used for treating graft vs. host disease (GvHD). The company is also testing Prochymal for treating Crohn’s disease in another Phase III trial. The Australian company Mesoblast is testing an ‘off-the-shelf’ mesenchymal precursor product candidate for treating patients with hematological malignancies.
Since 1968, bone marrow transplantation (BMT) has been the gold standard treatment for blood cancer patients and others with genetic blood disorders. Each year more than 60,000 bone marrow transplantations are performed worldwide, and 58% of these procedures use autologous bone marrow and 42% of the cases use allogeneic bone marrow. Currently, the use of bone marrow is being replaced by the utilization of MSCs for some conditions.
The majority of cell therapy products currently being marketed are meant to address musculoskeletal conditions, and most of these products use MSCs as a component.
The purpose of this report is to describe the current status of mesenchymal stem cells (MSCs) research, the ongoing clinical trials involving MSCs, late stage MSCs clinical trials, and the possible uses of MSCs in cell therapy. As MSC cell therapy is an integrated component of other cell therapies and regenerative medicines (RM), the report also gives a brief overview of the RM industry and overall cell therapy (CT) industry.
Thus, the main objectives are to consider the following:
Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular.
Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells.
Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types.
The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their sustained search for MSCs-based cell therapy products.
Key questions answered in this global strategic report are:
How many companies are currently supporting the RM industry?
What is the current regional breakdown of RM industry?
How many RM products have been approved?
What are the types of diseases are currently being pursued by RM companies?
What are the major financial events, partnerships and acquisitions in RM sector?
How do the large pharma companies perceive the value and long-term prospects of RM and CT?
What are the major anticipated RM clinical events in 2015-16?
What are the major therapeutic opportunities for the big pharma in RM and CT?
How many CT product candidates have reached the Phase III stage and what are they?
What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
What are the major commercially available cell therapy products?
What is the total number of cell therapy clinical trials at the global level?
What are the major cell types used in cell therapy clinical trials?
What are the major indications addressed by cell therapy clinical trials?
What are the major cell therapy clinical trials that have reached Phase III?
How many cell therapy clinical trials failed in the past year and what are they?
What are the contributions of MSCs to the cell therapy industry?
What are the biological properties of MSCs?
What do MSCs get differentiated into?
What bioactive molecules do the MSCs secrete?
What are the immunomodulatory functions of MSCs?
What are the factors impacting the acquisition of MSCs?
What are the various sources of MSCs?
What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
What are the major clinical trials focusing on diabetes using BMMSCs?
What are the major clinical trials involving BMMSCs for cardiovascular diseases?
What are the major clinical trials focusing on liver diseases by BMMSCs?
What are the brain-related diseases addressed by clinical trials using BMMSCs?
How many clinical trials are conducted for intestinal diseases using MSCs?
What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
Number of clinical trials using MSCs derived from Wharton’s jelly for various diseases?
What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
What is the current number of clinical trials using MSCs?
How many major clinical trials using MSCs have reached the Phase III?
What are the MSCs-based cell therapy products available in the market?
Inquiry on this report: http://www.researchmoz.us/enquiry.php?type=E&repid=301052
Table of Content
1. REPORT OVERVIEW
1.1 Statement of the Report
1.2 EXECUTIVE SUMMARY
2.1 Regenerative Medicine (RM) and Advanced Therapies Industry: A Brief Overview
2.2 Global Breakdown of Major RM Industries by Region
2.3 Breakdown of Global RM Companies by Type
2.4 Number of Therapeutic Companies, Approved Products and Clinical Trials in RM Sector
2.5 Number of RM Clinical Trials by Phase of Development
2.6 Number of RM Companies by Disease Focus Area
2.7 Major Financial Events in RM Industry
2.8 Major Partnerships and Acquisitions in RM Industry
2.9 Total Financings in RM Industry by Segment
2.10 Type of Financing for RM Industry
2.11 Major Regulatory Milestones in RM Industry
2.12 Major Data and Technology Events in RM Industry
2.13 Major Pharma and Biotech Companies Active in Advanced Therapies
2.14 Major Corporate Partnerships in RM Industry
2.15 Anticipated Major RM Clinical Events
2.16 Notable Deals and Acquisitions in RM, Cell and Gene Therapy Space, 2013-2014
2.17 Big Pharma’s Perception of RM
2.18.1 Major Therapeutic Opportunities for Big Pharma in Cell Therapy and RM
220.127.116.11 Current Opportunities
18.104.22.168 Near-Term Opportunities
22.214.171.124 Long-Term Opportunities
3. CELL THERAPY INDUSTRY: A BRIEF OVERVIEW
3.1 Types of Stem Cells Used in Cell Therapy
3.1.1 Human Embryonic Stem Cells (hESCs)
3.1.2 Induced Pluripotent Stem Cells (iPSCS)
3.1.3 Hematopoietic Stem Cells (HSCs)
3.1.4 Mesenchymal Stem Cells (MSCs)
3.1.5 Adipose Stem Cells (ASCs)
3.1.6 Neural Stem Cells (NSCs)
3.2 Cell Therapy Product Candidates in Late-Stage Clinical Development
3.3 Cell Therapy Product Candidates in Early-Stage Clinical Development
3.4 Cell Therapy Products Being Developed for Cardiovascular Indication
3.5 Cell Therapy Products Being Developed for Central Nervous System Indication
3.6 Cell Therapy Products Developed and Being Developed for Wound Care
3.7 Cell Therapy Products Developed and Being Developed for Spine and Orthopedics
3.8 Cell Therapy Products Being Developed for Diabetes
3.9 Cell Therapy Products Being Developed for Autoimmune Diseases
3.10 Combination of Cell and Gene Therapy Products in Development
3.11 Cancer Programs Utilizing the Combination of Cell and Immunotherapy
3.12 Major Commercially Available Cell Therapy Products
3.13 Cell Therapy Products Approved in South Korea
3.14 Cell Therapy Clinical Trials: An Overview
3.14.1 Cell Therapy Clinical Trials by Geography
3.14.2 Top Eight Countries in Cell Therapy Clinical Trials
3.14.3 Major Cell Types in Cell Therapy Clinical Trials
3.14.4 Major Disease Indications Addresses by Cell Therapy Clinical Trials
3.15 Fifteen Major Cell Therapies in Phase III
3.15.2 Mesenchymal Precursor Cell (MPC)
Browse All Biotechnology Market Research Reports at: http://www.researchmoz.us/biotechnology-market-reports-30.html
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives.